If you have been reading about thymosin beta-4 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-07-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 4963 Da for full-length thymosin beta-4 | Value applies to the parent protein; fragment products may differ |
| Appearance | White to off-white lyophilized powder | Typical form of supplied synthetic peptide |
| Solubility | Freely soluble in water | Polar peptide; dissolves readily in aqueous buffer |
| Storage of dry powder | −20 °C, desiccated, protected from light | Standard laboratory practice for peptides |
| Typical detection method | Liquid chromatography–tandem mass spectrometry | Used in purity testing and anti-doping analysis |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Subcutaneous fat is the most widely distributed subcutaneous tissue layer. It is composed of adipocytes, which are grouped together in lobules separated by connective tissue. The number of adipocytes varies among different body areas, while their size varies according to the body's nutritional state. It acts as padding and as an energy reserve, as well as providing some minor thermoregulation via insulation. Subcutaneous fat is found just beneath the skin, as opposed to visceral fat, which is found in the peritoneal cavity, and can be measured using body fat calipers to give a rough estimate of total body adiposity.
Synthetic cannabinoids, historically based on herbal cannabinoids, have been developed since the 1940s. Modern compounds may not resemble natural cannabinoids but are designed to interact with cannabinoid receptors. They are used to study structure-activity relationships but pose health risks when used recreationally. Examples include dronabinol, nabilone, and rimonabant.
About 82% of Americans live in metropolitan areas, particularly in suburbs and outer-ring exurbs; about half of those reside in cities with populations over 50,000. In 2024, 346 incorporated U.S. municipalities had populations over 100,000, 11 cities had more than one million residents, and four cities—New York City, Los Angeles, Chicago, and Houston—had populations exceeding two million. Some 56 U.S. metropolitan areas have one million or more residents. More recently, the fastest-growing metropolitan areas were in the South, while southern metros along the Mexican border and Gulf Coast metros susceptible to hurricanes declined the most in 2025. The New York metro area, which gained the most new residents in 2024, fell to 13th in 2025, due to a fall in immigrants. The top metro areas with rising populations in 2025 were Houston and Dallas–Fort Worth, followed by Atlanta, Phoenix and Charlotte.
=== Types of technology === Medical technology has evolved into smaller portable devices, for instance, smartphones, touchscreens, tablets, laptops, digital ink, voice and face recognition and more. With this technology, innovations like electronic health records (EHR), health information exchange (HIE), Nationwide Health Information Network (NwHIN), personal health records (PHRs), patient portals, nanomedicine, genome-based personalized medicine, Geographical Positioning System (GPS), radio frequency identification (RFID), telemedicine, clinical decision support (CDS), mobile home health care and cloud computing came to exist. Medical imaging and magnetic resonance imaging (MRI) have been long used and proven medical technologies for medical research, patient reviewing, and treatment analyzing. With the advancement of imagining technologies, including the use of faster and more data, higher resolution images, and specialist automation software, the capabilities of medical imaging technology are growing and yielding better results. As the imaging hardware and software evolve this means that patients will need to use less contrasting agents, and also spend less time and money. Further advancement in healthcare is electromagnetic (EM) technology guidance systems, used in medical procedures, allowing real-time visualization and navigation for the placement of medical devices inside the human body. For example, a neuro-navigated catheter is inserted into the brain, or a feeding tube placement in the stomach or small intestine, as demonstrated by the ENvue System.
=== Cancer treatment === Some preclinical and clinical research suggests that some beta blockers may be beneficial for cancer treatment. However, other studies do not show a correlation between cancer survival and beta blocker use. Also, a 2017 meta-analysis failed to show any benefit for the use of beta blockers in breast cancer.
Sources: en.wikipedia.org
In another phase II trial (006) of patients with relapsed and/or refractory multiple myeloma, carfilzomib in combination with lenalidomide and dexamethasone demonstrated an overall response rate of 69%. A phase II trial (007) for multiple myeloma and solid tumors showed promising results. In phase II trials of carfilzomib, the most common grade 3 or higher treatment-emergent adverse events were hematologic toxicity with thrombocytopenia, anemia, lymphopenia, neutropenia, pneumonia, fatigue and hyponatremia. In a frontline phase I/II study, the combination of carfilzomib, lenalidomide, and low-dose dexamethasone was highly active and well tolerated, permitting the use of full doses for an extended time in newly diagnosed multiple myeloma patients, with limited need for dose modification. Responses were rapid and improved over time, reaching 100% very good partial response. Furthermore, gastrointestinal disturbances, including diarrhea and nausea are non hematologic group of side effects commonly reported with proteasome inhibitors. Additionally, cardiovascular toxicity may be an outcome of carfilzomib treatment due to the effects on proteasomes in the myocardium. Thus, patient evaluation and risk assessment prior to initiation of therapy with carfilzomib is crucial.
persons and nationals." On March 6, 2026, Anthropic's CEO Dario Amodei stated that his company will challenge the DoD in court. Anthropic's partners, including Microsoft, Amazon and Google stated their agreement with Amodei. On March 8, 2026, OpenAI (the parent company of ChatGPT) announced that their head of robotics, Caitlin Kalinowski, had resigned stating, "surveillance of Americans without judicial oversight and lethal autonomy without human authorization are lines that deserved more deliberation than they got."
Former faculty member Ernest Lyon was a United States ambassador to Liberia and the founder of the Maryland Industrial and Agricultural Institute for Colored Youths. Noted African American historian and pioneering scholar Dr. Benjamin A. Quarles served on its faculty for many decades. Physician-scientist Charles R. Drew, known for his work on blood transfusion, was Morgan College's first athletic director. African-American historian Rosalyn Terborg-Penn wrote on women's suffrage. Flora E. Strout, Morgan College teacher and principal, wrote the school's anthem. Notable faculty currently teaching at Morgan State University include bestselling author and filmmaker MK Asante, and scholar Raymond Winbush.
== Other uses == Chicago Engineering Design Team, a robotics team Eau de toilette Editor (abbrev: "edt." pl.: "edts.") Electronic Disturbance Theater, an activist and artist collective Evidential decision theory, a school of thought within decision theory Event-driven trading, institutional investors attempt to profit from a stock mispricing that may occur during or after a corporate event.
Attempting to quit "cold turkey" may result in neurological damage due to excitotoxicity, severe physical injuries received during convulsions, and even death resulting from arrhythmias during grande Mal seizures, paralleling death caused by delirium tremens.
Sources: en.wikipedia.org
== History == Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis, but this trial was completed in October 2009. Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease, gout, and coronary artery disease (the CANTOS trial). It is also in trials for schizophrenia. In gout, it may result in better outcomes than a low dose of a steroid, but costs five thousand times more. The U.S. Food and Drug Administration (FDA) approved canakinumab for CAPS in June 2009, followed by the European Medicines Agency (EMA) in October. In August 2017, the results of the CANTOS trial were announced at the European Society of Cardiology. Those treated in CANTOS had a 15% reduction in deaths from heart attacks, stroke and cardiovascular disease combined. However, CANTOS reported serious side-effects and no statistically significant overall survival benefit.
G6P is then rearranged into fructose 6-phosphate (F6P) by glucose phosphate isomerase. Fructose can also enter the glycolytic pathway by phosphorylation at this point. The change in structure is an isomerization, in which the G6P has been converted to F6P. The reaction requires an enzyme, phosphoglucose isomerase, to proceed. This reaction is freely reversible under normal cell conditions. However, it is often driven forward because of a low concentration of F6P, which is constantly consumed during the next step of glycolysis. Under conditions of high F6P concentration, this reaction readily runs in reverse. This phenomenon can be explained through Le Chatelier's Principle. Isomerization to a keto sugar is necessary for carbanion stabilization in the fourth reaction step (below).
In chemistry, binding selectivity is defined with respect to the binding of ligands to a substrate forming a complex. Binding selectivity describes how a ligand may bind more preferentially to one receptor than another, or how a receptor may bind more preferentially one ligand than another. A selectivity coefficient is the equilibrium constant for the reaction of displacement by one ligand of another ligand in a complex with the substrate. Binding selectivity is of major importance in biochemistry and in chemical separation processes.
Interest in, and demand for, embalming grew steadily in the 19th century largely for sentimental reasons. People sometimes wished to be buried at far-off locations, which became possible with the advent of the railways, and mourners wanted the chance to pay their last respects beside the displayed body. Other motives behind embalming were prevention of disease and the wish to prepare funerals and burials, which were becoming more elaborate, without undue haste. After Lord Nelson was killed in the Battle of Trafalgar, his body was preserved in brandy and spirits of wine mixed with camphor and myrrh for over two months. At the time of his state funeral in 1805, his body was found to still be in excellent condition and completely plastic.
Sources: en.wikipedia.org
Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.
No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.
It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.